Insight Molecular Diagnostics (IMDX) EBT (2015 - 2026)

Insight Molecular Diagnostics has reported EBT for 12 years, with the latest figure at -$11.2 million in Q1 2026.

• Quarterly EBT fell 43.72% year-over-year to -$11.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$51.1 million (up 8.45% YoY) and the FY2025 annual result came in at -$59.7 million, up 52.45% from the prior year.
• EBT rose to -$11.2 million in Q1 2026 per IMDX's latest filing, from -$23.8 million in the prior quarter.
• Over five years, EBT peaked at $6.0 million in Q1 2023 and troughed at -$33.9 million in Q4 2024.
• A 5-year average of -$9.4 million and a median of -$8.3 million in 2023 frame the typical range for EBT.
• The widest YoY moves for EBT: up 274.6% in 2023, down 510.92% in 2023.
• Over 5 years, EBT stood at -$12.0 million in 2022, then slumped by 33.08% to -$16.0 million in 2023, then sank by 112.02% to -$33.9 million in 2024, then increased by 29.91% to -$23.8 million in 2025, then surged by 52.69% to -$11.2 million in 2026.
• According to Business Quant data, EBT over the past three periods registered -$11.2 million, -$23.8 million, and -$7.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.